http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2356998-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b81c3ecc9a3bd192c754216816991d8a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2257 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2010-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f202152f223bf8ccab51357cac7c63df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb22354fd7059c6e71539c4f9fdfd1c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2733203bff445613d8133e7cef67a45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fb610a9eee53a1d1624e987b87c401b |
| publicationDate | 2011-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2356998-A1 |
| titleOfInvention | A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein |
| abstract | The present invention refers to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of PAI-1 expression, which composition is comprising nA) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family and homologous derivatives thereof, which fragment comprises from 6 to 14 consecutive amino acid residues of the amino acid sequence having the following general formula (I): nX1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein nX1 is an amino acid residue of: Leu, Phe; nX2 is an amino acid residue of: Leu; nX3 is an amino acid residue of: Arg, Ser; nX4 is an amino acid residue of: Ile, Leu; nX5 is an amino acid residue of: Ser, Ile; nX6 is an amino acid residue of: Leu, Val; nX7 is an amino acid residue of: Leu, Ser, nX8 is an amino acid residue of: Leu, Ile; nX9 is an amino acid residue of: Ile, Leu; nX10 is an amino acid residue of: Gln, Glu, Arg; nX11 is an amino acid residue of: Ser; nX12 is an amino acid residue of: Trp; nX13 is an amino acid residue of: Leu, Asn; nX14 is an amino acid residue of: Glu (SEQ ID NO: 11); or n nB) a peptide or a recombinant protein comprising said peptide, wherein the peptide is from 6 to 50 amino acids in length and has the activity to inhibit plasminogen activator inhibitor I (PAI-1), said peptide comprising from 6 to 14 consecutive amino acid residues of the amino acid sequence of said general formula (I); or nC) a polynucleotide encoding said fragment of a polypeptide or protein of A) or said peptide or recombinant protein of B). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11524986-B2 |
| priorityDate | 2010-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.